<DOC>
	<DOC>NCT02229266</DOC>
	<brief_summary>The trial investigates the efficacy of adoptive immunotherapy with haploidentical natural killer cells compared to standard chemotherapy (after first complete remission) in patients with a high-risk acute myeloid leukemia being older than 65 years of age and not eligible for allogeneic transplantation</brief_summary>
	<brief_title>Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML</brief_title>
	<detailed_description>Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria In AML defined by cytogenetic aberrations the proportion of blasts may be &lt;20% Age ≥60 years Clinical performance corresponding to ECOG score 02 Highrisk karyotype &lt;5% myeloblasts in bone marrow ≥21 days after beginning of most recent chemotherapy maximal two preceding chemotherapy cycles Potentially available haploidentical family donor (child/ sibling), willing and fit for NK cell donation AML with favorable or intermediate risk cytogenetic features Persistent aplasia following preceding chemotherapy Relapsed or refractory AML Known preexisting autoimmune diseases Any severe concomitant condition which makes it undesirable for the patient to participate in the study Any condition which could jeorpadize compliance of the protocol Participation in another clinical trial during or within 4 weeks before study entry</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>high-risk AML</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>NK cells</keyword>
	<keyword>haploidentical natural killer cells</keyword>
	<keyword>immunotherapy</keyword>
</DOC>